AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 217 filers reported holding AMICUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $278,184 | -14.3% | 22,877 | -11.5% | 0.17% | -12.0% |
| Q2 2023 | $324,500 | +18.3% | 25,836 | +4.4% | 0.19% | +27.2% |
| Q1 2023 | $274,356 | -7.5% | 24,739 | +1.8% | 0.15% | -2.6% |
| Q4 2022 | $296,715 | -4.3% | 24,301 | -18.2% | 0.16% | +25.0% |
| Q3 2022 | $310,000 | -1.3% | 29,698 | +1.5% | 0.12% | +6.9% |
| Q2 2022 | $314,000 | -7.4% | 29,263 | -18.3% | 0.12% | -23.7% |
| Q1 2022 | $339,000 | -17.9% | 35,800 | 0.0% | 0.15% | -2.6% |
| Q4 2021 | $413,000 | +1.5% | 35,800 | -16.1% | 0.16% | -12.8% |
| Q3 2021 | $407,000 | -9.4% | 42,669 | -8.4% | 0.18% | -3.2% |
| Q2 2021 | $449,000 | +73.4% | 46,576 | +77.8% | 0.18% | +69.7% |
| Q1 2021 | $259,000 | -56.0% | 26,201 | +2.8% | 0.11% | -55.3% |
| Q4 2020 | $588,000 | -22.1% | 25,487 | -52.3% | 0.24% | -38.4% |
| Q3 2020 | $755,000 | +2.3% | 53,474 | +9.2% | 0.40% | +13.1% |
| Q2 2020 | $738,000 | +27.9% | 48,970 | -21.5% | 0.35% | +47.7% |
| Q1 2020 | $577,000 | -12.4% | 62,396 | -7.8% | 0.24% | +119.4% |
| Q4 2019 | $659,000 | +34.5% | 67,661 | +10.8% | 0.11% | +9.1% |
| Q3 2019 | $490,000 | -44.9% | 61,053 | -14.4% | 0.10% | -47.3% |
| Q2 2019 | $890,000 | -11.2% | 71,320 | -3.2% | 0.19% | -91.2% |
| Q1 2019 | $1,002,000 | +82.2% | 73,653 | +28.3% | 2.13% | +2168.1% |
| Q4 2018 | $550,000 | +57.6% | 57,427 | +99.1% | 0.09% | +161.1% |
| Q3 2018 | $349,000 | -54.8% | 28,845 | -41.7% | 0.04% | -94.7% |
| Q2 2018 | $772,000 | -12.8% | 49,455 | -15.9% | 0.68% | -11.1% |
| Q1 2018 | $885,000 | +125.8% | 58,836 | +116.0% | 0.77% | +56.1% |
| Q4 2017 | $392,000 | -31.9% | 27,241 | -28.7% | 0.49% | +530.8% |
| Q3 2017 | $576,000 | +64.6% | 38,223 | +10.1% | 0.08% | +50.0% |
| Q2 2017 | $350,000 | +2.6% | 34,727 | -27.4% | 0.05% | -14.8% |
| Q1 2017 | $341,000 | +58.6% | 47,843 | +10.6% | 0.06% | -4.7% |
| Q4 2016 | $215,000 | -28.6% | 43,256 | +6.3% | 0.06% | -56.2% |
| Q3 2016 | $301,000 | +35.6% | 40,705 | 0.0% | 0.15% | -11.5% |
| Q2 2016 | $222,000 | -4.3% | 40,705 | +48.5% | 0.16% | -48.4% |
| Q1 2016 | $232,000 | – | 27,420 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |